FunPep Company Limited (JP:4881)

:4881

4881

FunPep Company Limited

RESEARCH TOOLSreports

FunPep Company Limited (4881) Price & Analysis

0 Followers

4881 Stock Chart & Stats

¥79.00

¥1.00(0.72%)

At close: Jan 08 4:00 PM EST

¥79.00

¥1.00(0.72%)

Day’s Range― - ―

52-Week Range¥75.00 - ¥130.00

Previous CloseN/A

Volume532.20K

Average Volume (3M)245.82K

Market Cap

¥3.72B

Enterprise Value¥1.59B

Total Cash (Recent Filing)¥2.33B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.06

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.06

Shares Outstanding44,846,700

10 Day Avg. Volume262,310

30 Day Avg. Volume245,823

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.13

Price to Sales (P/S)9943.96

P/FCF Ratio-2.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-34.5

Revenue Forecast (FY)¥500.00M

Bulls Say, Bears Say

Bulls Say

Proprietary Peptide Platform And Immunotherapy FocusFunPep's proprietary peptide platform and focus on immunotherapy represent a durable scientific asset. Platform technologies can generate multiple programs, lower marginal R&D cost per new candidate, and attract partner interest over years, supporting long-term program optionality and licensing value.

Licensing And Partnership-driven Revenue ModelA licensing and partnership model is structurally aligned with small biotech economics: it enables non-dilutive milestone and royalty streams, outsources costly late-stage development and commercialization, and can extend runway through partner-funded trials, improving scalability without proportional fixed-cost growth.

Low Financial Leverage — Zero Total DebtHaving no debt materially reduces refinancing and covenant risk for an early-stage biotech. This clean capital structure preserves strategic flexibility for licensing deals or equity raises, lowering near-term solvency risk and enabling management to pursue partnerships without interest obligations.

Bears Say

Severe 2025 Revenue CollapseA ~94% revenue drop in 2025 is a structural red flag: it curtails milestone and royalty inflows, undermines partner confidence, and signals program setbacks or lost contracts. Such a collapse materially impairs predictable cash generation and reduces the company's ability to finance R&D organically over the medium term.

Accelerating Operating Cash BurnOperating cash flow deteriorated sharply, indicating the business is not self-funding and cash consumption is rising. Accelerating burn increases near-term funding and dilution risk, forces more frequent capital raises, and constrains long-term program execution unless partnership or financing outcomes improve.

Deepening Losses And Equity ErosionWidening net losses and marked equity decline over years signal persistent negative returns and shareholder value erosion. This trend limits balance sheet resilience, increases reliance on dilution to fund operations, and raises long-term sustainability concerns if operating leverage and revenue recovery are not achieved.

4881 FAQ

What was FunPep Company Limited’s price range in the past 12 months?

FunPep Company Limited lowest stock price was ¥75.00 and its highest was ¥130.00 in the past 12 months.

What is FunPep Company Limited’s market cap?

FunPep Company Limited’s market cap is ¥3.72B.

When is FunPep Company Limited’s upcoming earnings report date?

FunPep Company Limited’s upcoming earnings report date is May 18, 2026 which is in 45 days.

How were FunPep Company Limited’s earnings last quarter?

FunPep Company Limited released its earnings results on Feb 12, 2026. The company reported -¥17.06 earnings per share for the quarter, missing the consensus estimate of N/A by -¥17.06.

Is FunPep Company Limited overvalued?

According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FunPep Company Limited pay dividends?

FunPep Company Limited does not currently pay dividends.

What is FunPep Company Limited’s EPS estimate?

FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FunPep Company Limited have?

FunPep Company Limited has 44,846,700 shares outstanding.

What happened to FunPep Company Limited’s price movement after its last earnings report?

FunPep Company Limited reported an EPS of -¥17.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.97%.

Which hedge fund is a major shareholder of FunPep Company Limited?

Currently, no hedge funds are holding shares in JP:4881

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FunPep Company Limited

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.